Form 8-K - Current report:
SEC Accession No. 0001214659-24-000421
Filing Date
2024-01-08
Accepted
2024-01-08 17:02:09
Documents
13
Period of Report
2024-01-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 o152468k.htm   iXBRL 8-K 46924
2 EXHIBIT 2.1 ex2_1.htm EX-2 343869
  Complete submission text file 0001214659-24-000421.txt   641985

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE hgen-20240103.xsd EX-101.SCH 2991
4 XBRL LABEL FILE hgen-20240103_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE hgen-20240103_pre.xml EX-101.PRE 22343
7 EXTRACTED XBRL INSTANCE DOCUMENT o152468k_htm.xml XML 3026
Mailing Address 830 MORRIS TURNPIKE 4TH FLOOR SHORT HILLS NJ 07078
Business Address 830 MORRIS TURNPIKE 4TH FLOOR SHORT HILLS NJ 07078 (973) 200-3100
HUMANIGEN, INC (Filer) CIK: 0001293310 (see all company filings)

EIN.: 770557236 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35798 | Film No.: 24520923
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)